[Studies of thyroid tissue following treatment of hyperthyroidism with I131. 2. Dosages and frequencies of I131 administration with the dosages less than 10 mci].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Hirose.
Explore the source record for details and available documents.
A reappraisal was made of the relationship between exposure to atomic radiation in 1945 and the occurrence of salivary gland tumors in heavily exposed survivors. This was made possible by the discovery of 8 additional patients; the total now reported consists of 30 cases. In those exposed to 300+ rads, the number of cases was significantly (p less than .01) greater than expected. This was found for the combined group and for malignant types, but not for histologically benign tumors. Our prior conclusion regarding the high-dose radiation effect upon salivary gland neoplasia remains unchanged in the reanalysis; however, our suggestion that younger persons were at significantly greater risk is weakened.
Myelolipoma of the adrenal gland is a rare tumor. It has been surgically excised in only five cases, including the one described in this report. However, review of the literature reveals a total of one hundred thirty cases. Although more than 96 per cent of these lesions were found incidentally at autopsy and more than half could be appreciated only microscopically, it is clear that these tumors can grow sufficiently to become symptomatic, undergo hemorrhage, and require operation. The clinical angiographic and pathologic features of myelolipoma are described. Although endocrine function of this tumor has never been demonstrated, related experimental evidence of others is summarized because it suggests that complete endocrinologic evaluation of patients with suspected myelolipoma is indicated. Despite the rarity of the tumor, we believe that the radiologic and clinical features of myelolipoma that we have described may allow preoperative diagnosis in the future.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.